Remune Plus Drugs For HIV

24 February 1997

Immune Response has started a 32-week Phase II trial of its HIVimmunotherapeutic Remune (gp120-depleted HIV-immunogen) in combination with triple antiretroviral therapy consisting of Glaxo Wellcome's reverse transcriptase inhibitors Retrovir (zidovudine) and Epivir (lamivudine) and Merck & Co's protease inhibitor Crixivan (indinavir).

Immune Response notes that progression to AIDS seems to occur as a result of a loss of HIV-specific immunity, on which antiviral drugs have little impact. Combining antivirals and Remune, which appears to augment HIV-specific immunity, it adds, may offer synergies.

The trial will enroll 150 HIV-positive individuals with CD4 counts greater than 400/mm3.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight